LXR stimulates a metabolic switch and reveals cholesterol homeostasis as a statin-target against Tasmanian Devil Facial Tumor Disease

Published: 16 February 2021| Version 1 | DOI: 10.17632/44ky4hzhcw.1
Contributors:
Manuel Fernandez-Rojo,

Description

This is raw data related to the manuscript "LXR stimulates a metabolic switch and reveals cholesterol homeostasis as a statin-target against Tasmanian Devil Facial Tumor Disease"

Files

Steps to reproduce

DFTD4 cells were lysed in cold RIPA buffer containing protease (Merck Pty Ltd, Kilsyth, Australia) and phosphatase (Roche Diagnostics, Castle Hill, Australia) inhibitors and stored at −20°C. Protein concentrations were determined using a Pierce BCA Protein assay kit (Thermo Fisher Scientific). Samples were subjected to SDS-PAGE and blotted according to standard procedures. In brief, 10 μg of protein was loaded per lane. Antibodies used for western blots are Phosphorylated AKT Threonine-308, Phosphorylated AKT Serine-473 and Total AKT (Cell signalling) and HRP-secondary antibodies (Sigma). Protein signals were visualized using enhanced chemiluminescence (Pierce™ ECL Western Blotting Substrate).